Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough?
Open Access
Abstract
This review article is an overview of the session at the European Society for Medical Oncology (ESMO) Asia 2018 Congress entitled: 'Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough?'. The article provides an overview of the session speakers' views on the impact that the lack of accessibility and availability of medicines has on patient outcomes in the treatment of breast cancer, colorectal cancer and lung cancer, responsible for more than one-third of cancer deaths in the Asian region. It also lists the various global policy initiatives that ESMO supports to promote the best cancer care in the Asian and Asia-Pacific region. The review presents extrapolated data from the 'ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe', which reveals several disparities among Asian countries, across the different income levels. In low- and middle-income countries, some barriers to the accessibility of anticancer medicines include the lack of government reimbursement, budget allocation for healthcare and quality-assured generic and biosimilar medicines, as well as shortages and patent rights. Throughout the article, the session presenters provide their views on strategies that can be considered to overcome these barriers.Keywords
This publication has 33 references indexed in Scilit:
- Policies and Programs to Facilitate Access to Targeted Cancer Therapies in ThailandPLOS ONE, 2015
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast CancerNew England Journal of Medicine, 2015
- Using TRIPS flexibilities to facilitate access to medicinesBulletin of the World Health Organization, 2013
- The global cancer divide: Relationships between national healthcare resources and cancer outcomes in high-income vs. middle- and low-income countriesJournal of Epidemiology and Global Health, 2013
- First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the LungJournal of Clinical Oncology, 2012
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Expansion of cancer care and control in countries of low and middle income: a call to actionThe Lancet, 2010
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast CancerNew England Journal of Medicine, 2005
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998